FDA Approves Enjaymo (sutimlimab-jome) for Use in Patients with Cold Agglutinin Disease

Paris, February 4, 2022. The U.S. Food and Drug Administration (FDA) has approved Enjaymo™ (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD). Enjaymo is the…Original Article